Marker Therapeutics, Inc. (MRKR)
NASDAQ: MRKR · Real-Time Price · USD
1.430
+0.020 (1.42%)
At close: May 21, 2026, 4:00 PM EDT
1.448
+0.018 (1.27%)
After-hours: May 21, 2026, 6:22 PM EDT
Marker Therapeutics Revenue
Marker Therapeutics had revenue of $751.69K in the quarter ending March 31, 2026, with 115.32% growth. This brings the company's revenue in the last twelve months to $3.95M, down -30.67% year-over-year. In the year 2025, Marker Therapeutics had annual revenue of $3.55M, down -46.19%.
Revenue (ttm)
$3.95M
Revenue Growth
-30.67%
P/S Ratio
6.72
Revenue / Employee
$709,334
Employees
5
Market Cap
23.84M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.55M | -3.04M | -46.19% |
| Dec 31, 2024 | 6.59M | 3.28M | 99.06% |
| Dec 31, 2023 | 3.31M | -5.70M | -63.26% |
| Dec 31, 2022 | 9.01M | 7.77M | 625.90% |
| Dec 31, 2021 | 1.24M | 774.93K | 166.01% |
| Dec 31, 2020 | 466.79K | 253.59K | 118.95% |
| Dec 31, 2019 | 213.19K | 7.20K | 3.50% |
| Dec 31, 2018 | 205.99K | 22.93K | 12.53% |
| Dec 31, 2017 | 183.06K | -48.14K | -20.82% |
| Dec 31, 2016 | 231.20K | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Celularity | 26.55M |
| Traws Pharma | 2.73M |
| Pluri | 1.08M |
| Vistagen Therapeutics | 789.00K |
| VYNE Therapeutics | 454.00K |
| Allarity Therapeutics | 345.00K |
MRKR News
- 4 days ago - Marker Therapeutics Quarterly report: Q1 2026 - Filings
- 4 days ago - Marker Therapeutics Earnings release: Q1 2026 - Filings
- 2 months ago - Marker Therapeutics Proxy statement: Proxy filing - Filings
- 2 months ago - Marker Therapeutics Proxy statement: Proxy filing - Filings
- 2 months ago - Marker Therapeutics reports FY25 EPS (79c), two estimates (94c) - TheFly
- 2 months ago - Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results - GlobeNewsWire
- 2 months ago - Marker Therapeutics Earnings release: Q4 2025 - Filings
- 2 months ago - Marker Therapeutics Annual report: Q4 2025 - Filings